Regulatory News:

ACTICOR BIOTECH (FR0014005OJ5 - ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, today provides an update on the call for tenders launched on 12 September 2024, with a view to a restructuring plan (plan de continuation), or sale under the current receivership procedure (plan de cession).

On September 13 2024, the court-appointed administrator (administrateur judiciaire) has published an advertisement in the newspaper Les Echos seeking new investors to provide a restructuring plan (plan de continuation, articles L.626-1 et seq. of the French Commercial Code), or failing that, potential buyers for the business and assets of the Company (plan de cession, articles L.642-1 et seq. of the French Commercial Code).

With no response to date, and to enable the Company to continue its search for new investors or partners to support its new development plan in STEMI (ST-Elevation Myocardial Infarction), the court-appointed administrator has granted an extension of the invitation to tender until Tuesday 5 November 2024 at 12:00 pm.

Interested parties wishing to respond to the extended call for tenders are invited to express their interest by e-mail to the following addresses:

  • Marine Pace: m.pace@aj-2m.com
  • Roxane Brodin: r.brodin@aj-2m.com

For further information: acticor-biotech.com

A new announcement to this effect was also published today by the court-appointed administrator on several specialized online platforms (including Mayday, ASPAJ, CNAJMJ).

As a reminder, on 6 August 2024, the Paris Commercial Court ordered the opening of receivership proceedings. The purpose of these proceedings is to enable the Company to assess all the options available to it to pursue its development, the development of its product, glenzocimab, and its search for financing and partners. This procedure will also enable the Company to finance its operations until January 2025.

About ACTICOR BIOTECH

ACTICOR BIOTECH, a clinical-stage biopharmaceutical company founded in 2013 from the work of INSERM, is developing glenzocimab, a humanized monoclonal antibody fragment (fab) targeting the GPVI platelet receptor for the treatment of cardiovascular emergencies and acute thrombotic diseases.

The main clinical indication being evaluated is acute ischemic stroke, due to the strong need for safer treatments, particularly those that do not increase the risk of bleeding, and its high incidence. In three international clinical trials involving over 600 stroke patients, no significant impact on neurological improvement (mRS score at 3 months) was demonstrated, with the exception of a sub-population of patients with intracerebral haemorrhage, where mortality was significantly reduced by a factor of 3 (p=0.035) (Mazighi et al. 2024).

LIBERATE, a Phase 2 clinical trial in the acute phase of myocardial infarction (STEMI), is currently being recruited through an academic partnership with the University of Birmingham (UK). This study aims to demonstrate the efficacy of glenzocimab in reducing the size of myocardial infarction, a critical factor for long-term cardiac function.

In all, more than 800 subjects were included in the clinical trials, over 400 of whom were exposed to glenzocimab without safety concerns.

The use of glenzocimab in thrombotic diseases is covered by 3 patent families, with an expiry date in 2036 for the first family. ACTICOR BIOTECH also has the right to develop a biomarker for stroke patients.

Acticor Biotech is backed by a panel of European and international investors (Mediolanum farmaceutici, Karista, Go Capital, Newton Biocapital, CMS Medical Venture Investment (HK) Limited, A&B (HK) Limited, Anaxago, and the Armesa Foundation) and has been listed on Euronext Growth Paris since November 2021 (ISIN: FR0014005OJ5 - ALACT).

For further information, visit: www.acticor-biotech.com

Disclaimer

This press release contains forward-looking statements with respect to Acticor Biotech and its business. Acticor Biotech believes that these forward-looking statements are based on reasonable assumptions. However, no assurance can be given that the expectations expressed in such forward-looking statements will prove to have been correct, as they are subject to risks, including those described in the Universal Registration Document as filed with the Autorité des marchés financiers on July 9, 2024, and to changes in economic conditions, financial markets and the markets in which Acticor Biotech operates. The forward-looking statements contained in this press release are also subject to risks that are unknown to Acticor Biotech or that Acticor Biotech does not currently consider material. The occurrence of some or all of these risks could cause Acticor Biotech's actual results, financial condition, performance or achievements to differ materially from those expressed in the forward-looking statements.

ACTICOR BIOTECH Gilles AVENARD, MD CEO and Founder gilles.avenard@acticor-biotech.com

Sophie BINAY, PhD General Manager and CSO Sophie.binay@acticor-biotech.com

NewCap Mathilde BOHIN Investor Relations acticor@newcap.eu T. : +33 (0)1 44 71 94 95

NewCap Arthur ROUILLÉ Media Relations acticor@newcap.eu T. : +33 (0)1 44 71 00 15

Acticor Biotech (EU:ALACT)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024 Plus de graphiques de la Bourse Acticor Biotech
Acticor Biotech (EU:ALACT)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024 Plus de graphiques de la Bourse Acticor Biotech